HGP1201 + HIP1402

**HGP1201 + HIP1402** refers to the co-administration of two investigational drugs developed by Hanmi Pharmaceutical, studied together as a combination therapy. This combination has been evaluated in Phase 1 clinical trials for pharmacokinetic interactions and safety in healthy male volunteers, with indications targeting urogenital disorders such as **erectile dysfunction** and **prostatic hyperplasia**. Both agents are described as small molecule drugs, but their specific individual mechanisms of action, molecular targets, or pharmacology have not been detailed in publicly available sources. The combination has not progressed past Phase 1 development status, and there are no public reports of regulatory approval, detailed results, or use outside of clinical trials[1][4][6].